Related Experiment Video
Updated: Jan 16, 2026
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Optimizing Vagus Nerve Stimulation Parameters in Pediatric Drug-Resistant Epilepsy: A Retrospective Two-Center Study
Müge Baykan1, Özge Baykan Çopuroğlu2, Elif Didinmez Taşkırdı3
1Department of Pediatric Neurology, Rize Training and Research Hospital, Recep Tayyip Erdoğan University, Rize 53020, Turkey.
Insights
Vagus nerve stimulation (VNS) effectively reduces seizures in drug-resistant epilepsy (DRE) in children. Optimal results for pediatric DRE were achieved with an output current of 1.5 mA and a 10% duty cycle.
Area of Science:
- Pediatric Neurology
- Neuroscience
- Medical Devices
Background:
- Drug-resistant epilepsy (DRE) poses a significant challenge in pediatric neurology.
- Vagus nerve stimulation (VNS) is an adjunctive therapy for DRE, but optimal parameters for children are not well-established.
- Current pediatric VNS protocols are often based on adult data.
Purpose of the Study:
- To evaluate the clinical effectiveness of VNS in pediatric DRE.
- To identify stimulation thresholds, specifically output current and duty cycle, associated with seizure reduction in children.
- To inform individualized, age-specific VNS programming strategies.
Main Methods:
- Retrospective analysis of 52 pediatric patients (0-18 years) with DRE undergoing VNS.
- VNS parameters: fixed frequency (30 Hz) and pulse width (250 µs); titrated output current and duty cycle.
- Seizure outcomes assessed via caregiver diaries and clinical visits; treatment response defined as ≥50% seizure frequency reduction.
Main Results:
- At 12 months, 76.9% of patients achieved ≥50% seizure reduction.
- 32.7% experienced ≥90% seizure reduction, and 11.5% achieved complete seizure freedom.
- Optimal outcomes correlated with approximately 1.5 mA output current and 10% duty cycle.
Conclusions:
- VNS is a highly effective and well-tolerated treatment for pediatric DRE.
- An output current of 1.5 mA and a 10% duty cycle may be a useful programming target for pediatric VNS.
- Individualized, age-specific stimulation strategies are recommended to optimize VNS outcomes in children.
Objectives:
Drug-resistant epilepsy (DRE) remains a major challenge in pediatric neurology, as many children fail to achieve seizure control despite appropriate medications. Vagus nerve stimulation (VNS) offers an effective adjunctive treatment; however, optimal stimulation parameters for children are not well defined and are often extrapolated from adult protocols. This retrospective two-center cohort study aimed to evaluate the clinical effectiveness of VNS in pediatric DRE and to determine stimulation thresholds-particularly output current and duty cycle-most strongly associated with seizure reduction.
Methods:
Fifty-two pediatric patients (aged 0-18 years) with DRE who underwent VNS implantation and were followed for at least 12 months were retrospectively analyzed. Stimulation frequency and pulse width were fixed at 30 Hz and 250 µs, while output current and duty cycle were titrated based on clinical response. Seizure outcomes were derived from caregiver-maintained seizure diaries and confirmed during structured follow-up visits. Treatment response was defined as a ≥50% reduction in seizure frequency compared to baseline.
Results:
At 12 months post-implantation, 76.9% of patients achieved ≥ 50% seizure reduction, 32.7% experienced ≥ 90% reduction, and 11.5% attained complete seizure freedom. Optimal outcomes were associated with output currents of approximately 1.5 mA and duty cycles of 10%.
Conclusions:
VNS is a highly effective and well-tolerated treatment for pediatric DRE. Stabilization at an output current of 1.5 mA and a 10% duty cycle may serve as a clinically useful programming target. These findings support the use of individualized, age-specific stimulation strategies to optimize outcomes in pediatric VNS therapy.
